PDF herunterladen
Semin Respir Crit Care Med 2003; 24(3): 287-296
DOI: 10.1055/s-2003-41089
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pulmonary Hypertension in the Collagen Vascular Diseases

Lynn T. Tanoue
  • Yale University School of Medicine, Section of Pulmonary and Critical Care Medicine, New Haven, Connecticut
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. August 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Pulmonary hypertension is increasingly recognized as a complication of the collagen vascular diseases. Both isolated and secondary forms of the disease may be appreciated. Pulmonary hypertension is observed with high prevalence in scleroderma and mixed connective tissue disease. It is less commonly seen in systemic lupus erythematosus, and is a rare clinical finding in rheumatoid arthritis. The diagnosis and treatment of pulmonary hypertension associated with the collagen vascular diseases mirror diagnosis and treatment for pulmonary hypertension of any etiology. Vasodilator therapy may play a particularly important role in patients with the isolated form of disease, which is most frequently associated with scleroderma.

KEYWORDS

Pulmonary hypertension - collagen vascular disease - scleroderma - mixed connective tissue disease - systemic lupus erythematosus

REFERENCES

  • 1 Roncoroni A J, Alvarez C, Molinas F. Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus.  Respiration . 1992;  59 52-56
    PubMedGoogle Scholar
  • 2 Murin S, Wiedemann H P, Matthay R A. Pulmonary manifestations of systemic lupus erythematosus.  Clin Chest Med . 1998;  19 641-665
    PubMedGoogle Scholar
  • 3 Kishida Y, Kanai Y, Kiramochi S. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus.  J Rheumatol . 1993;  20 2161-2162
    PubMedGoogle Scholar
  • 4 Colby T V. Pulmonary pathology in patients with systemic autoimmune diseases.  Clin Chest Med . 1998;  19 587-612
    CrossrefPubMedGoogle Scholar
  • 5 Palevsky H I, Gurughagavatula I. Pulmonary hypertension in collagen vascular disease.  Comp Ther . 1999;  25 133-143
    PubMedGoogle Scholar
  • 6 LeRoy E C. Pulmonary hypertension: the bete noire of the diffuse connective tissue diseases.  Am J Med . 1991;  90 539-540
    PubMedGoogle Scholar
  • 7 LeRoy E C, Black C, Fleischmajer R. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.  J Rheumatol . 1988;  15 202-205
    PubMedGoogle Scholar
  • 8 Nishimaki T, Aotsuka S, Kondo H. et al . Immunological analysis of pulmonary hypertension in connective tissue diseases.  J Rheumatol . 1999;  26 2357-2362
    PubMedGoogle Scholar
  • 9 Alarcon-Segovia D, Eeleze M, Oria C V. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients.  Medicine . 1989;  68 353-365
    PubMedGoogle Scholar
  • 10 Asherson R A, Hackett D, Gharavi A E, Harris E N, Kennedy H G, Hughes G R. Pulmonary hypertensiion in systemic lupus erythematosus: a report of three cases.  J Rheumatol . 1986;  13 416-420
    PubMedGoogle Scholar
  • 11 Asherson R A, Cervera R. Review: antiphospholipid antibodies and the lung.  J Rheumatol . 1995;  22 62-66
    PubMedGoogle Scholar
  • 12 Asherson R A, Higenbottam T W, Dinh Xuan T A. Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients.  J Rheumatol . 1990;  17 1292
    PubMedGoogle Scholar
  • 13 Gussin H AE, Ignat G P, Varga J, Teodorescu M. Anti-topoisomerase I (Anti-Scl-70) antibodies in patients with systemic lupus erythematosus.  Arthr Rheum . 2001;  44 376-383
    CrossrefPubMedGoogle Scholar
  • 14 Yoshio T, Masuyama J, Sumiya M. Antiendothelial cell antibodies and their relation to pulmonary hypertension insystemic lupus erythematosus.  J Rheumatol . 1994;  21 2058-2063
    PubMedGoogle Scholar
  • 15 Quismorio F P, Sharma O, Koss M. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus.  Semin Arthritis Rheum . 1984;  13 349-359
    CrossrefPubMedGoogle Scholar
  • 16 Yeo P PB, Sinniah R. Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies.  Ann Rheum Dis . 1975;  34 457-458
    PubMedGoogle Scholar
  • 17 Sanchez O, Humberg M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases.  Thorax . 1999;  54 273-277
    PubMedGoogle Scholar
  • 18 Sanchez O, Humbert M, Sitbon O, Nunes H, Garcia G, Simonneau G. Pulmonary hypertension associated with connective tissue diseases.  Revue de Medecine Interne . 2002;  23 41-54
    PubMedGoogle Scholar
  • 19 Goupille P, Fauchier L, Babuty D. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus.  J Rheumatol . 1994;  21 1976-1977
    PubMedGoogle Scholar
  • 20 Groen H, Bootsma H, Postma D S. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide.  J Rheumatol . 1993;  20 1055-1057
    PubMedGoogle Scholar
  • 21 Mahowald M L, Weir E K, Ridley D J. Pulmonary hypertension in systemic lupus ereythematosus: effect of vasodilators on pulmonary hemodynamics.  J Rheumatol . 1985;  12 773-777
    PubMedGoogle Scholar
  • 22 Minai O A, Dweik R A, Arroliga A C. Manifestations of scleroderma pulmonary disease.  Clin Chest Med . 1998;  713-731
    CrossrefPubMedGoogle Scholar
  • 23 Battle R W, Davitt M A, Cooper S M. et al . Prevalence of pulmonary hypertension in limited and diffuse scleroderma.  Chest . 1996;  110 1515-1519
    CrossrefPubMedGoogle Scholar
  • 24 Bolster M B, Silver R M. Lung disease in systemic sclerosis (scleroderma).  Bailliere's Clin Rheum . 1993;  7 79-97
    PubMedGoogle Scholar
  • 25 Coghlan J G, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology.  Curr Opinion Rheumatol . 2001;  13 495-499
    PubMedGoogle Scholar
  • 26 Stupi A, Steen V, Owens G. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.  Arthritis Rheum . 1986;  29 515-524
    CrossrefPubMedGoogle Scholar
  • 27 Ungerer R G, Tashkin D P, Furst D. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.  Am J Med . 1983;  75 65-74
    PubMedGoogle Scholar
  • 28 D'Angelo W A, Fries J F, Masi A T. Pathologic observations in systemic sclerosis (scleroderma).  Am J Med . 1969;  46 428-440
    CrossrefPubMedGoogle Scholar
  • 29 Owens G R, Follansbee W P. Cardiopulmonary manifestations of systemic sclerosis.  Chest . 1987;  91 118-127
    PubMedGoogle Scholar
  • 30 Yousem S A. The pulmonary pathologic manifestations of the CREST syndrome.  Hum Pathol . 1990;  21 467-474
    CrossrefPubMedGoogle Scholar
  • 31 Kerin K, Yost J H. Advances in the diagnosis and management of scleroderma-related vascular complications.  Comp Ther . 1998;  24 574-581
    PubMedGoogle Scholar
  • 32 Steen V D, Powell D L, Medsger Jr A T. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.  Arthritis Rheum . 1988;  31 196-203
    CrossrefPubMedGoogle Scholar
  • 33 Denton C P, Cailes J B, Phillips G D, Wells A U, Black C M, Du Bois M R. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.  British J Rheumatol . 1997;  36 239-243
    CrossrefPubMedGoogle Scholar
  • 34 Murata I, Takenaka K, Yoshinoya S. et al . Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders.  Chest . 1997;  111 36-43
    PubMedGoogle Scholar
  • 35 Wallman L L, Penny R, Williamson D J. Pulmonary vascular aspects of systemic sclerosis.  Aust NZ J Med . 1996;  26 150-153
    PubMedGoogle Scholar
  • 36 Christman B W, McPherson C D, Newman J H. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.  N Engl J Med . 1992;  327 70-75
    CrossrefPubMedGoogle Scholar
  • 37 Vancheeswaran R, Magoulas I, Efrat G. Circulating endothelin-1 in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction?.  J Rheumatol . 1994;  21 1838-1844
    PubMedGoogle Scholar
  • 38 Stewart D J, Levy R D, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?.  Ann Intern Med . 1991;  114 464-469
    CrossrefPubMedGoogle Scholar
  • 39 Giaid A, Yanagisawa M, Langleben D. Expression of endothelin-1 in the lungs of patients with pulmonary hypertensiion.  N Engl J Med . 1993;  328 1732-1739
    CrossrefPubMedGoogle Scholar
  • 40 Duchman S M, Thohan V, Kaira D. Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure.  Curr Opin Cardiol . 2002;  15 136-140
    PubMedGoogle Scholar
  • 41 Harvey A O, Shulman L E, Tulmulty P A, Conley C L, Schoenrich E H. Systemic lupus erythematosus: review of the literature and clinical anaysis of 138 cases.  Medicine . 1954;  33 291-437
    PubMedGoogle Scholar
  • 42 Cervera R, Khamashta M A, Font J. et al . Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients.  Medicine . 1972;  72 113-124
    PubMedGoogle Scholar
  • 43 Winslow T M, Ossipov M A, Fazio G P, Simonson J S, Redberg R F, Schiller N B. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus.  Am Heart J . 1995;  129 510-515
    CrossrefPubMedGoogle Scholar
  • 44 Simonson J S, Schiller N B, Petri M, Hellmann D B. Pulmonary hypertension in systemic lupus erythematosus.  J Rheumatol . 1989;  16 918-925
    PubMedGoogle Scholar
  • 45 Grigor R, Edmonds J, Lewkonia R. Systemic lupus erythematosus: a prospective analysis.  Ann Rheum Dis . 1978;  37 121-128
    CrossrefPubMedGoogle Scholar
  • 46 Gross M, Esterly J R, Earle R H. Pulmonary alterations in systemic lupus erythematosus.  Am Rev Respir Dis . 1972;  105 572-577
    PubMedGoogle Scholar
  • 47 Miyata M, Suzuki K, Sakuma F. Anticardiolipin antibodies are associated wirth pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus.  Int Arch Allergy Immunol . 1993;  100 351-354
    PubMedGoogle Scholar
  • 48 Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance.  Ann Intern Med . 1990;  112 682-698
    CrossrefPubMedGoogle Scholar
  • 49 Roberts W C, High S T. The heart in systemic lupus erythematosus.  Curr Probl Cardiol . 1999;  24 1-56
    PubMedGoogle Scholar
  • 50 Cheng T O. Pulmonary hypertension in systemic lupus erythematosus.  Mayo Clin Proc . 1999;  74 845
    PubMedGoogle Scholar
  • 51 Wilson L, Tomita T, Braniecki M. Fatal pulmonary hypertension in identical twins with systemic lupus erythematosus.  Hum Pathol . 1991;  22 295-297
    CrossrefPubMedGoogle Scholar
  • 52 Evans J. Antinuclear antibody testing in systemic autoimmune disease.  Clin Chest Med . 1998;  19 613-625
    CrossrefPubMedGoogle Scholar
  • 53 Burdt M, Hoffman R W, Deutscher S L, Wang G S, Johnson J C, Sharp G. Long-term outcome in mixed connective tissue disease.  Arthr Rheum . 1999;  42 899-909
    CrossrefPubMedGoogle Scholar
  • 54 Sharp G C, Irvin W S, Tan E M, Gould R G, Holman R H. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen.  Am J Med . 1972;  52 148-159
    CrossrefPubMedGoogle Scholar
  • 55 Prakash U BS. Respiratory complications in mixed connective tissue disease.  Clin Chest Med . 1999;  19 733-746
    PubMedGoogle Scholar
  • 56 Wiener-Kronish J P, Soloinger A M, Warnock M L, Churg A, Ordonez N, Golden J A. Severe pulmonary involvement in mixed connective tissue disease.  Am Rev Respir Dis . 1981;  124 499-503
    PubMedGoogle Scholar
  • 57 Sullivan W D, Hurst D J, Harmon C E. et al . A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.  Medicine . 1984;  63 92-107
    CrossrefPubMedGoogle Scholar
  • 58 Fujii M, Adachi S, Shimizu T. Interstitial lung disease in rheumatoid arthritis: assessment with high-resolution computed tomography.  J Thorac Imag . 1993;  8 54-62
    PubMedGoogle Scholar
  • 59 Gabbay E, Tarala R, Will R. Interstitial lung disease in recent onset rheumatoid arthritis.  Am J Respir Crit Care Med . 1997;  156 528-535
    CrossrefPubMedGoogle Scholar
  • 60 Remy-Jardin M, Remy J, Cortet B. Lung changes in rheumatoid arthritis: CT findings.  Radiology . 1994;  193 375-382
    CrossrefPubMedGoogle Scholar
  • 61 Tanoue L T. Pulmonary manifestations of rheumatoid arthritis.  Clin Chest Med . 1998;  19 667-685
    CrossrefPubMedGoogle Scholar
  • 62 Gardner D L, Duthie J R, MacLeod J, Allen W SH. Pulmonary hypertension in RA: report of a case study with intimal sclerosis of pulmonary and digital arteries.  Scott Med J . 1957;  2 183-186
    PubMedGoogle Scholar
  • 63 Helmers R, Galvin J, Hunninghake G W. Pulmonary manifestations associated with rheumatoid arthritis.  Chest . 1991;  100 235-238
    PubMedGoogle Scholar
  • 64 Dawson J K, Goodson N G, Graham D R, Lynch M P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients.  Rheumatology . 2000;  39 1320-1325
    CrossrefPubMedGoogle Scholar
  • 65 Okano Y, Steen V D, Medsger T A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemc sclerosis.  Arthritis Rheum . 1992;  35 95-100
    CrossrefPubMedGoogle Scholar
  • 66 Rich S, Levy P S. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension.  Am J Med . 1984;  76 573-578
    CrossrefPubMedGoogle Scholar
  • 67 Fuster V, Steele P M, Edwards W D, Gersh B, McGoon M, Frye R L. Primary pulmonary hypertension: natural history and the importance of thrombosis.  Circulation . 1984;  70 580-587
    CrossrefPubMedGoogle Scholar
  • 68 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.  N Engl J Med . 1992;  327 76-81
    CrossrefPubMedGoogle Scholar
  • 69 Barst R J, Rubin L J, Long W A. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.  N Engl J Med . 1996;  334 296-302
    CrossrefPubMedGoogle Scholar
  • 70 McLaughlin V V, Genthner D E, Panella M M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.  N Engl J Med . 1998;  338 273-277
    CrossrefPubMedGoogle Scholar
  • 71 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation . 2002;  106 1477-1482
    CrossrefPubMedGoogle Scholar
  • 72 Badesch D B, Tapson V F, McGoon M D. et al . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease.  Ann Intern Med . 2000;  132 425-434
    PubMedGoogle Scholar
  • 73 Menon N, McAlpine L, Peacock A J, Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.  Arthr Rheum . 1998;  41 466-469
    CrossrefPubMedGoogle Scholar
  • 74 Klings E S, Hill N S, Leong M H, Simms R W, Korn J H, Farber H W. Systemic sclerosis-associated pulmonary hypertension.  Arthr Rheum . 1999;  42 2638-2645
    CrossrefPubMedGoogle Scholar
  • 75 Strange C, Bolster M, Mazur J, Taylor M, Gossage J R, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.  Chest . 2000;  118 1077-1082
    CrossrefPubMedGoogle Scholar
  • 76 Sitbon O, Humbert M, Sanchez O. Survival in pulmonary hypertension associated with connective tissue diseases (PH-CTD) treated with long-term epoprostenol (PGI2): comparison with primary pulmonary hypertension (PPH).  Am J Respir Crit Care Med . 1999;  159 A158
    PubMedGoogle Scholar
  • 77 Barst R J. Experience and reason.  Chest . 2000;  117 2-5
    CrossrefPubMedGoogle Scholar
  • 78 Robbins I M, Gaine S P, Schilz R, Tapson V F, Rubin L J, Loyd J E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.  Chest . 2000;  117 14-18
    CrossrefPubMedGoogle Scholar
  • 79 Horn E M, Barst R J, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.  Chest . 2000;  118 1229-1230
    CrossrefPubMedGoogle Scholar
  • 80 Galie N, Grigioni F, Bacchi-Reggiani L. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension.  Eur J Clin Invest . 1996;  26 A48
    PubMedGoogle Scholar
  • 81 Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phonomenon and systemic sclerosis.  Intern Med . 1994;  33 579-582
    PubMedGoogle Scholar
  • 82 Chatterjee K, De Marco T, Alpert J S. Pulmonary hypertension: hemodynamic diagnosis and management.  Arch Intern Med . 2002;  162 1925-1933
    CrossrefPubMedGoogle Scholar
  • 83 Williamson D J, Wallman L L, Jones R. et al . Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.  Circulation . 2000;  102 411-418
    PubMedGoogle Scholar
  • 84 Channick R N, Simonneau G, Sitbon O. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study.  Lancet . 2001;  358 1119-1123
    CrossrefPubMedGoogle Scholar
  • 85 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med . 2002;  346 896-903
    CrossrefPubMedGoogle Scholar
  • 86 Lepore J J, Marco A, Pereira N L. et al . Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension.  Am J Cardiol . 2002;  90 677-680
    CrossrefPubMedGoogle Scholar
  • 87 Rosas I, Conte J, Yang S. Lung transplantation and systemic sclerosis.  Ann Transplantation . 2000;  5 38-43
    PubMedGoogle Scholar
  • 88 Arcasoy S M, Kotloff R M. Lung transplantation.  N Engl J Med . 1999;  340 1081-1091
    CrossrefPubMedGoogle Scholar